A new study details how a nasal spray formulated by investigators from Brigham and Women's Hospital may work to protect ...

Study found OV329 cleared and remained undetectable in the retina, eye, and brain tissues of mice, unlike vigabatrin which has repeatedly shown ...

Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the ...

MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic ...

Dr. Jeremy Farrar, WHO’s Chief Scientist, emphasized the importance of strengthening country-led R&D and integrating clinical ...

KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic diseaseKT-621 ...

YourChoice Therapeutics has dosed the first cohort of male subjects in a Phase Ia/IIb clinical trial of YCT-529, a ...

Vivani Medical today announced that Australian authorities approved a first-in-human clinical trial for its subdermal GLP-1 ...

ASP-2138 is a bispecific antibody targeting CD3 and claudin 18.2 (CLDN18.2). It is administered through intravenous drip ...

PharmaLegacy Laboratories, a provider of in vitro and in vivo preclinical drug development services, has acquired BTS ...

The option gives Glaukos exclusive global license agreements on pre-agreed terms, including upfront and milestone payments ...